Vaccines save lives by protecting people against infectious diseases — polio, influenza, and pneumonia to name a few. Kaiser Permanente Washington Health Research Institute (KPWHRI) is working to protect communities through research to continually improve the safety and effectiveness of vaccines for infectious diseases of public health importance.
Central to this work is testing new vaccines against emerging diseases — such as COVID-19. In March 2020, KPWHRI gave the world’s first-ever injection of an investigational vaccine for COVID-19 in a phase 1 clinical trial led by Senior Investigator Lisa A. Jackson, MD, MPH. We continue to be at the forefront of efforts to understand and combat COVID-19. To learn more, see COVID-19 research at KPWHRI.
Successes over 3 decades of KPWHRI vaccine research include:
Our current research projects on vaccines and infectious diseases include:
Kenigsberg TA, Goddard K, Hanson KE, Lewis N, Klein N, Irving SA, Naleway AL, Crane B, Kauffman TL, Xu S, Daley MF, Hurley LP, Kaiser R, Jackson LA, Jazwa A, Weintraub ES. Simultaneous administration of mRNA COVID-19 bivalent booster and influenza vaccines. Vaccine. 2023 Sep 7;41(39):5678-5682. doi: 10.1016/j.vaccine.2023.08.023. Epub 2023 Aug 19. PubMed
Tchesnokova V, Larson L, Basova I, Sledneva Y, Choudhury D, Solyanik T, Heng J, Bonilla TC, Pham S, Schartz EM, Madziwa LT, Holden E, Weissman SJ, Ralston JD, Sokurenko EV. Increase in the community circulation of ciprofloxacin-resistant Escherichia coli despite reduction in antibiotic prescriptions. Commun Med (Lond). 2023 Aug 12;3(1):110. doi: 10.1038/s43856-023-00337-2. PubMed
Rouphael NG, Branche AR, Diemert DJ, Falsey AR, Losada C, Baden LR, Frey SE, Whitaker JA, Little SJ, Kamidani S, Walter EB, Novak RM, Rupp R, Jackson LA, Babu TM, Kottkamp AC, Luetkemeyer AF, Immergluck LC, Presti RM, Bäcker M, Winokur PL, Mahgoub SM, Goepfert PA, Fusco DN, Atmar RL, Posavad CM, Netzl A, Smith DJ, Telu K, Mu J, McQuarrie LJ, Makowski M, Makhene MK, Crandon S, Montefiori DC, Roberts PC, Beigel JH. Immunogenicity of a two dose regimen of Moderna mRNA Beta/Omicron BA.1 bivalent variant vaccine boost in a randomized clinical trial. J Infect Dis. 2023 Aug 10;jiad323. doi: 10.1093/infdis/jiad323. Online ahead of print. PubMed
Williamson BD, Magaret CA, Karuna S, Carpp LN, Gelderblom HC, Huang Y, Benkeser D, Gilbert PB. Application of the SLAPNAP statistical learning tool to broadly neutralizing antibody HIV prevention research. iScience. 2023 Aug 9;26(9):107595. doi: 10.1016/j.isci.2023.107595. eCollection 2023 Sep 15. PubMed
Katherine Yih W, Daley MF, Duffy J, Fireman B, McClure DL, Nelson JC, Qian L, Smith N, Vazquez-Benitez G, Weintraub E, Williams JTB, Xu S, Maro JC. Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink. Vaccine. 2023 Aug 14;41(36):5265-5270. doi: 10.1016/j.vaccine.2023.07.010. Epub 2023 Jul 20.m PubMed
Lisa A. Jackson, MD, MPHSenior Investigator |
Jennifer C. Nelson, PhDDirector, Biostatistics; Senior Investigator |
Andrea J. Cook, PhDSenior Biostatistics Investigator |
Sascha Dublin, MD, PhDSenior Investigator |
Onchee Yu, MSPrincipal Collaborative Biostatistician |
Robert D. Wellman, MSPrincipal Collaborative Biostatistician |
Clarissa Hsu, PhDAssociate Investigator |
Brian D. Williamson, PhDAssistant Biostatistics Investigator |
Noorie Hyun, PhDAssociate Biostatistics Investigator |
Pamela A. Shaw, PhD, MSSenior Biostatistics Investigator |
Annie Piccorelli, PhDSenior Collaborative Biostatistician |
Doug Opel, MD, MPH
University of Washington (UW) Department of Bioethics and Humanities; UW Department of Pediatrics; UW Medical Center
John Dunn, MD, MPH
Kaiser Foundation Health Plan of Washington
Elizabeth Lin, MD, MPH
Kaiser Foundation Health Plan of Washington Family Practice;
Kaiser Permanente Washington Health Research Institute